Special report: vaccines for the treatment of malignant melanoma
BlueCross BlueShield Association
Record ID 32003000738
English
Authors' objectives:
The specific objectives of this special report are informational in nature, as follows:
- to review the immunologic principles supporting the development of a melanoma vaccine; - to review the various biologic approaches being taken to develop a melanoma vaccine, especially those that have resulted in phase III trials; - to review the results of completed phase III trials of melanoma vaccines, and to summarize active and recently closed phase III trial protocols; - to summarize and evaluate the evidence from phase I/II trials of those melanoma vaccines currently in phase III trials.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Vaccination
- Melanoma
- Skin Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.